[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
April 14, 2010

FDA Offers Advice to Reduce Risks of Long-Acting β-Agonists in Asthma Care

JAMA. 2010;303(14):1353-1354. doi:10.1001/jama.2010.357

Long-acting β-agonists (LABAs) should never be used to treat asthma without a corticosteroid or other asthma controller medication, according to new recommendations from the US Food and Drug Administration (FDA) aimed at reducing rare but serious adverse events associated with these drugs. Even use of combination products should be limited to instances in which it is absolutely necessary, the agency advised.

First Page Preview View Large
First page PDF preview
First page PDF preview